Deals Of The Week: Pfizer/Humana, Teva/Par, Bayer/Yunona
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
GlycoMimetics’ Sickle Cell Candidate Nearly Ready For Hand-Over To Pfizer
Biotech focused on role of carbohydrates in biological processes completes Phase II program of lead candidate for sickle cell disease. Under a 2011 partnership, Pfizer takes over development of GMI-1070 in Phase III.
Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis
Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.
Pfizer Research Partnership With Humana Could Inform Drug Development Decisions
Pfizer and Humana announce five-year partnership to explore ways to improve the quality, outcomes and cost of health care for seniors using medical claims data from Humana's research affiliate, Competitive Health Analytics.